Abbott Exercises its Option to Acquire Cephea Valve Technologie
Abbott to acquire Cephea Valve, in all stock transaction, with its heart valve replacement technology
The focus of the acquisition is to utilize Cephea’s technology in developing therapies for mitral valve disease while strengthening Abbott’s footprints in heart therapies
Cephea’s Technology develops an artificial valve, delivered through veins in the leg for patients in need of mitral valves replacements. Additionally, In 2009, Abbott acquired Evalve with its MitraClip technology for repairing leaky heart valves marketed in EU in 2008 and the US in 2013
Click here to read full press release/ article | Ref: Abbott | Image: Crain Chicago Business
Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at email@example.com.